文献速递艾滋病与性传播感染新发突发、热带与寄生虫病

严重急性呼吸综合征冠状病毒2(SARS-CoV-2)感染与Ad26.CoV2.S疫苗接种在HIV感染者中的免疫原性

Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection and Ad26.CoV2.S Vaccination in People Living With Human Immunodeficiency Virus (HIV).
PubMed 文献 · Clin Infect Dis · 2022-01-01

研究评估Ad26.CoV2.S疫苗在HIV感染者中诱导针对Delta变异株中和活性的能力,并比较HIV状态及病毒抑制对未接种感染者Delta中和反应的影响。结果显示,HIV控制良好的接种者中和反应不劣于HIV阴性者,而未接种的HIV感染者中和反应降低,病毒血症者降低最明显。

要点

  • HIV控制良好的Ad26.CoV2.S接种者Delta中和反应不劣于HIV阴性者。
  • 既往感染加接种者Delta中和较仅感染组高9倍,较仅接种组高26倍。
  • 未接种的HIV感染者中和反应较对照低7倍,无应答者频率更高,病毒血症者最高。

核心结论

  • HIV控制良好的PLWH接种Ad26.CoV2.S后对Delta变异株的中和反应不劣于HIV阴性者,无论既往是否感染SARS-CoV-2。
  • 在SARS-CoV-2感染且未接种者中,HIV感染降低对SARS-CoV-2的中和反应,HIV病毒血症者降低最明显。

研究设计与样本

  • 研究纳入通过SISONKE南非Ad26.CoV2.S疫苗临床试验接种的医护人员,其中PLWH为HIV感染控制良好者。
  • 同时纳入既往感染SARS-CoV-2的未接种参与者。
  • 采用活病毒中和试验评估对Delta变异株的中和能力。

主要发现

  • 多数Ad26.CoV2.S接种的医护人员既往感染过SARS-CoV-2。
  • 在该组中,Delta变异株中和较仅感染组高9倍,较仅接种组高26倍。
  • PLWH相对HIV阴性者未观察到Delta变异株中和下降。
  • SARS-CoV-2感染且未接种的PLWH中和低7倍,无应答者频率更高,HIV病毒血症者无应答频率最高。
  • 仅接种者中和能力低。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: People living with HIV (PLWH) have been reported to have a higher risk of more severe COVID-19 disease and death. We assessed the ability of the Ad26.CoV2.S vaccine to elicit neutralizing activity against the Delta variant in PLWH relative to HIV-negative individuals. We also examined effects of HIV status and suppression on Delta neutralization response in SARS-CoV-2-infected unvaccinated participants. METHODS: We enrolled participants who were vaccinated through the SISONKE South African clinical trial of the Ad26.CoV2.S vaccine in healthcare workers (HCWs). PLWH in this group had well-controlled HIV infection. We also enrolled unvaccinated participants previously infected with SARS-CoV-2. Neutralization capacity was assessed by a live virus neutralization assay of the Delta variant. RESULTS: Most Ad26.CoV2.S vaccinated HCWs were previously infected with SARS-CoV-2. In this group, Delta variant neutralization was 9-fold higher compared with the infected-only group and 26-fold higher relative to the vaccinated-only group. No decrease in Delta variant neutralization was observed in PLWH relative to HIV-negative participants. In contrast, SARS-CoV-2-infected, unvaccinated PLWH showed 7-fold lower neutralization and a higher frequency of nonresponders, with the highest frequency of nonresponders in people with HIV viremia. Vaccinated-only participants showed low neutralization capacity. CONCLUSIONS: The neutralization response of the Delta variant following Ad26.CoV2.S vaccination in PLWH with well-controlled HIV was not inferior to HIV-negative participants, irrespective of past SARS-CoV-2 infection. In SARS-CoV-2-infected and nonvaccinated participants, HIV infection reduced the neutralization response to SARS-CoV-2, with the strongest reduction in HIV viremic individuals.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Khan K, Lustig G, Bernstein M, et al. Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection and Ad26.CoV2.S Vaccination in People Living With Human Immunodeficiency Virus (HIV). Clin Infect Dis. 2022. PMID: 34893824. doi:10.1093/cid/ciab1008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。